[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neonatal-jaundice\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neonatal-jaundice":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,71,99,125,175,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100622628","the-effect-of-skin-color-scale-material-used-by-families-at-home-in-the-postnatal-period-on-the-process-of-hospital-admission-due-to-jaundice-and-breastfeeding-parameters-100622628",false,"NCT07386093","The Effect of Skin Color Scale Material Used by Families at Home in the Postnatal Period on the Process of Hospital Admission Due to Jaundice and Breastfeeding Parameters","Inclusion Criteria:\n\n* Preterm infants born alive between 36-42 weeks of gestation or delivered healthy to their mothers,\n* Newborns with a birth weight of 2500 grams or more,\n* Newborns without a history of multiple pregnancy (twins, triplets, etc.),\n* Newborns with at least one literate parent,\n* Newborns whose families voluntarily agree to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Newborns younger than 36 weeks and requiring intensive care, or newborns older than 42 weeks,\n* Newborns weighing less than 2500 grams at birth,\n* Newborns requiring postnatal intensive care,\n* Newborns with congenital anomalies, metabolic diseases, or serious clinical problems,\n* Newborns whose families wish to withdraw from the study during the follow-up period or whose contact information is unavailable,\n* Newborns excluded from analysis due to incomplete or erroneous data,\n* Newborns whose families did not sign the informed consent form.",true,"ALL","36 Weeks","42 Weeks",{"count":20,"type":21},128,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this research is to evaluate the effect of the Skin Color Scale Material used by families in the postnatal period on the hospital admission process due to jaundice and breastfeeding parameters.\n\nAlthough neonatal jaundice is mostly physiological, it can lead to serious complications such as kernicterus if not detected in time. Visually supported educational materials developed to provide early awareness can help families both to regularly monitor the baby's skin color and to notice the signs of jaundice in time.",[27],"Neonatal Jaundice",[29,30],"newborn","neonatal jaundice","NOT_YET_RECRUITING","2026-01-27",{"date":34,"type":35},"2026-02-04","ACTUAL",{"date":37,"type":21},"2026-01-20",{"date":39,"type":21},"2026-06-30",{"name":41,"class":42},"Istanbul University - Cerrahpasa","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100617169","reliability-of-transcutaneous-bilirubin-measurement-according-to-the-skin-colour-of-newborns-100617169","NCT07315126","Reliability of Transcutaneous Bilirubin Measurement According to the Skin Colour of Newborns","BILICOLOR","Inclusion Criteria:\n\n* Born from 36 weeks of amenorrhea\n* Hospitalized in the postnatal ward or kangaroo care unit\n* Requiring a blood test for bilirubin analysed at the Cochin laboratory.\n* No objection from both holders of parental authority.\n\nExclusion Criteria:\n\n* Having received phototherapy treatment within the last 24 hours","1 Hour","7 Days",{"count":53,"type":21},510,"OBSERVATIONAL","Neonatal jaundice is a physiological process characterized by a yellow coloration of the skin and mucous membranes linked to an increase in a pigment: bilirubin. However, an excessive accumulation of bilirubin can lead to neurological complications: kernicterus. The screening for pathological jaundice is carried out through daily measurements of transcutaneous bilirubin using non-invasive devices (bilirubinometers). The diagnosis is made by measuring blood bilirubin levels and comparing them with reference curves. In newborns with dark skin, transcutaneous bilirubin measurements may be inaccurate because melanin interferes with the bilirubinometers.",[27],[58,59,60],"Neonatal jaundice","Kernicterus","Newborn","2025-12-17",{"date":63,"type":35},"2026-01-02",{"date":65,"type":21},"2026-03",{"date":67,"type":21},"2027-04",{"name":69,"class":42},"Assistance Publique - Hôpitaux de Paris",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":70},"100390597","bubolight-a-new-phototherapy-device-for-the-treatment-of-the-newborns-jaundice-100390597","NCT04365998","BUBOLight®, a New Phototherapy Device for the Treatment of the Newborn's Jaundice","Use of \"BUBOLight®\" Device as an Innovative Phototherapy Device for the Treatment of Newborn's Jaundice. A Monocentric, Descriptive Pilot Study, for the Feasibility, Safety and Tolerance of the BUBOLight® Device","BUBO","Inclusion Criteria:\n\n* At time of birth, infant is \\> 35 weeks gestation\n* Presence of jaundice confirmed by measurement of bilirubin (transcutaneous bilirubinometer)\n* Total bilirubinemia rate requiring phototherapy according to National Institute for Health and Clinical Excellence.\n* Weight ≥2.500kg\n* Judged in good health by the investigator following the clinical examination and the medical data (absence of perinatal asphyxia, antibiotic treatment, respiratory disorders)\n* Absence of fœto-maternal rhesus incompatibility or Kell\n\nExclusion Criteria:\n\n* Newborn already treated with phototherapy\n* Febrile state with body temperature \\> 37.8°C\n* Total bilirubinaemia level is equal or excess 100 μmol \u002F L of the indication of phototherapy.\n* Patient whose jaundice is due to haemolysis, obstruction functional or anatomical.\n* Minor relative\n* Newborn requiring exchange transfusion\n* Newborn with congenital erythropoietic porphyria or a family history of porphyria.\n* Patient requiring treatment other than phototherapy","30 Days",{"count":81,"type":21},15,[24],"About 50% of full-term newborns and 80% of premature infants develop jaundice which is due to hyperbilirubinemia. In the majority of cases, jaundice disappears naturally without treatment within three weeks of birth, but the bilirubin level may remain too high, which can lead to a serious neurological disease: kernicterus. To avoid this, a therapeutic management must be instituted, and in some cases, one or more phototherapy sessions (PT) may be prescribed.\n\nThe aim of this trial is to evaluate the safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy BUBOLight® included two removable strips of luminous textile incorporating optical fibers.\n\n10 newborns requiring phototherapy, will be illuminated during four hours in one session of PT Bilirubin levels is taken at the start of phototherapy H0 and Controls are made at H+6 hours.",[27],[86,87,88,29],"jaundice","phototherapy","medical device","RECRUITING","2025-12-16",{"date":92,"type":35},"2025-12-23",{"date":94,"type":35},"2020-10-08",{"date":96,"type":21},"2026-12",{"name":98,"class":42},"University Hospital, Lille",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":70},"100590133","neoscb-app-for-screening-jaundice-in-newborns-100590133","NCT06963450","NeoSCB App for Screening Jaundice in Newborns","Clinical Investigation of the Smartphone App neoSCB to Perform Neonatal Jaundice Screening in Newborn Babies","neoSCB","Inclusion Criteria:\n\n* Term newborn babies with and without jaundice (postnatal age 0 day to 28 days)\n\nExclusion Criteria:\n\n* Newborn babies who are clinically unwell and require urgent medical attention, and babies who have received phototherapy recently","28 Days",{"count":109,"type":21},405,"About 60% of babies born after 36 weeks of pregnancy have jaundice during the first two weeks of life. Due to the accumulation of bilirubin in the bloodstream, jaundiced babies appear yellow, which allows healthcare professionals to visually identify significantly jaundiced babies. They will be referred for a blood test to determine if the bilirubin level is so high that treatment such as phototherapy, or more intensive help is required. Left untreated or treatment delayed, jaundice can potentially result in serious brain damage and even death (rare). However, visual inspection of jaundiced babies is inaccurate, often need to unnecessary referrals to hospital blood tests. We have developed the \"neoSCB\" smartphone app, which accurately detects significant jaundice by taking photographs of the baby's sclera (white part of an eye) and analysing its yellowness using a diagnostic algorithm. The neoSCB app has previously been validated in Ghana involving over 700 newborn babies. In this new study, we will recruit 405 newborn babies with a range of jaundice levels to validate an optimised diagnostic algorithm following our latest research. Two existing commercial screening devices will also be used to investigate whether the app delivers a similar accuracy, at a fraction of the cost. We will enhance the usability of the app and add new features following feedback from patients and healthcare professionals. A health economic study will be conducted to evaluate the economic benefits to the NHS.",[27],[113,114,115,30],"screening","newborn babies","mobile app","2025-12-03",{"date":118,"type":35},"2025-12-04",{"date":120,"type":35},"2025-09-23",{"date":122,"type":21},"2027-03-31",{"name":124,"class":42},"University College, London",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":133,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":158,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":70},"100598934","comparing-integrative-midwife-led-vs-fragmented-inpatient-postpartum-care-impact-on-satisfaction-and-transition-to-motherhood-100598934","NCT07077941","Comparing Integrative Midwife-led vs. Fragmented Inpatient Postpartum Care: Impact on Satisfaction and Transition to Motherhood","Supporting Mothers With Integrative Care by Midwives for Lifelong Empowerment (SMILE): A Randomized Controlled Trial Comparing Midwife-led Integrative and Fragmented Standard Inpatient Postpartum Care Models on Maternal Satisfaction and Transition to Motherhood","SMILE","Inclusion Criteria:\n\n* Women aged 18 to 50 years at the time of delivery\n* Classified as \"low-risk\" by the obstetric team in the delivery room\n* Gestational age at birth between 36+0 and 42+0 weeks\n* Singleton birth (only one child born)\n* Intent to breastfeed\n* Consent to participate in the study\n\nExclusion Criteria:\n\n* Women younger than 18 or older than 50 at the time of delivery\n* Classified as \"high-risk\" by the obstetric team\n* Multiple birth (e.g., twins, triplets)\n* No intention or ability to breastfeed the newborn","FEMALE","18 Years","50 Years",{"count":137,"type":21},784,[24],"The goal of this clinical trial is to compare two different forms of postnatal care to find out which is most beneficial for mothers and their children after birth and with which they are most satisfied. One is a nurse-led, seperate model of care and the other is a midwife-led, integrative model of care. Participants are healthy women between the ages of 18 and 50. They gave birth between 36+0 and 42+0 weeks of pregnancy and had a child. The type of birth is not an inclusion or exclusion criteria. Our hypotheses are: i) that maternal satisfaction with care in a midwife-led, integrative care model is higher than in separate maternal and infant care; ii) that a positive postpartum experience leads to earlier and increased maternity competence; iii) that a higher breastfeeding rate at the time of the survey in the fourth month can be achieved through integrative care. Participants will be randomly assigned, after birth of their child, to either the group cared for by a nurse or the group cared for by a midwife.",[141,142,143,144,145,146,147,148,149,150,27,151,152,153,154,155,156,157],"Maternal Health Services","Infant, Newborn","Postnatal Care","Breast Feeding","Maternal-Child Relations","Postpartum Depression (PPD)","Mental Health","Lactation","Breast Feeding, Exclusive","Patient Satisfaction and Experience With Integrative Therapies","Maternal Behavior","Body Weight Decreased","Breast Feeding of Healthy Full Term Infants","Lactation Mastitis","Lactation Disorder - Postpartum Condition or Complication","Lactation Disorder With Baby Delivered","Lactation; Insufficient, Partial",[159,160,161,162,163,164,165],"Postnatal care","inpatient","maternity competence","satisfaction","integrative care","breastfeeding","maternal behavior","2025-07-12",{"date":168,"type":35},"2025-07-22",{"date":170,"type":21},"2025-10-01",{"date":172,"type":21},"2026-12-31",{"name":174,"class":42},"Medical University of Vienna",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100564403","liver-biopsy-in-diagnosis-neonatal-jaundice-100564403","NCT06628726","Liver Biopsy in Diagnosis Neonatal Jaundice","Role of Liver Biopsy As a Diagnostic Tool for Neonatal Jaundice Causes","Inclusion Criteria:\n\n* All cases presented with persistent neonatal jaundice in the first year of life in 5 years interval (2019-2023), received at Surgical Pathology Laboratory at Assiut University Hospitals, Egypt.\n\nExclusion Criteria:\n\n* Patients older than one year.\n* Patients who underwent liver biopsy in the same age group but were not diagnosed as Persistent Neonatal Jaundice.\n* Patients with deficient clinical data.","1 Month","1 Year",{"count":185,"type":21},50,[24],"1. Identification and characterization of histopathological features of liver in cases of PNJ.\n2. Assessment of key histological features in liver biopsy as diagnostic parameters in differentiating intra-hepatic and extra-hepatic causes of PNJ.\n3. Evaluation of role of liver biopsy as a diagnostic tool in conjunction with clinical and laboratory findings.",[189,27],"Neonatal Cholestasis",[191,189,192],"liver biopsy in neonatal jaundice","liver biopsy","2024-10-04",{"date":195,"type":35},"2024-10-08",{"date":197,"type":21},"2024-11-01",{"date":199,"type":21},"2025-12",{"name":201,"class":42},"Assiut University",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":15,"sex":16,"minAge":209,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":70},"100479332","evaluation-of-a-smartphone-based-screening-tool-picterus-jp-for-neonatal-jaundice-chicago-100479332","NCT05521607","Evaluation of a Smartphone-based Screening Tool (Picterus JP) for Neonatal Jaundice (Chicago)","Evaluation of a Smartphone-based Screening Tool (Picterus JP) for Neonatal Jaundice in Newborns with High Melanin Content (Chicago)","Inclusion Criteria:\n\n* Infants born with gestational age \\> 35 weeks.\n* Birth weight ≥ 1800 grams\n* Age 1 - 14 days\n* Infants requiring a TSB blood sample for clinically suspected jaundice as part of standard care\n\nExclusion Criteria:\n\n* Infants showing signs of inborn disease.\n* Infants with skin rash or other skin disease that affects the skin where measurements are performed.\n* Infants transferred to the pediatric ward for medical treatment.\n* Infants that have received phototherapy in the last 24 hours","1 Day","14 Days",{"count":212,"type":21},250,[24],"A cross-sectional conductive study at the University of Chicago Medicine facilities (hospital and outreach clinics) to enable high qualitative estimation of bilirubin levels in the blood of newborns, independent of skin color, using Picterus JP.",[27],"2024-09-13",{"date":218,"type":35},"2024-09-19",{"date":220,"type":35},"2023-01-06",{"date":222,"type":21},"2025-06-15",{"name":224,"class":225},"Picterus AS","INDUSTRY"]